Michele Korfin
Directeur/Membre du Conseil chez ORGANOGENESIS HOLDINGS INC.
Fortune : 334 146 $ au 30/04/2024
Postes actifs de Michele Korfin
Sociétés | Poste | Début | Fin |
---|---|---|---|
ORGANOGENESIS HOLDINGS INC. | Directeur/Membre du Conseil | 03/05/2022 | - |
Independent Dir/Board Member | 03/05/2022 | - | |
BioNJ, Inc.
BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart. | Directeur/Membre du Conseil | - | - |
Secrétaire Général | 13/02/2020 | - |
Historique de carrière de Michele Korfin
Anciens postes connus de Michele Korfin
Sociétés | Poste | Début | Fin |
---|---|---|---|
GAMIDA CELL LTD. | Directeur des opérations | 01/08/2020 | 01/04/2024 |
TYME TECHNOLOGIES, INC. | Directeur des opérations | 15/03/2019 | 01/01/2020 |
Corporate Officer/Principal | 15/10/2018 | 15/03/2019 | |
KITE PHARMA INC | Corporate Officer/Principal | 01/01/2016 | 01/07/2018 |
CELGENE | Corporate Officer/Principal | 01/01/2004 | 01/03/2016 |
Formation de Michele Korfin
Harvard Business School | Masters Business Admin |
Rutgers State University of New Jersey | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 9 |
Opérationnelle
Corporate Officer/Principal | 3 |
Chief Operating Officer | 2 |
Director/Board Member | 2 |
Sectorielle
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
GAMIDA CELL LTD. | Health Technology |
ORGANOGENESIS HOLDINGS INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Tyme Technologies, Inc.
Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ. | Health Technology |
BioNJ, Inc.
BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart. | Commercial Services |
Kite Pharma, Inc.
Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Bourse
- Insiders
- Michele Korfin
- Expérience